Navigation Links
Mayo Clinic finds withdrawing ventricular assist device support ethical
Date:8/2/2010

ROCHESTER, Minn. - Patients have the right to refuse or request the withdrawal of any unwanted treatment. In an article published in the online issue of Mayo Clinic Proceedings, investigators explore the legal and ethical permissibility of carrying out such a request specific to a ventricular assist device (VAD).

The left-VAD (LVAD) is a new technology that provides circulatory support for patients with severe heart failure who are awaiting a heart transplant. This technology also can serve as a long-term treatment option for patients who are not candidates for heart transplant, but still need circulatory support, also known as "destination therapy."

Notably, VAD technology is continuously improving. "A recent trial demonstrated significantly greater two-year survival among patients with severe heart failure treated with continuous-flow LVADs than among patients treated with older pulsatile-flow devices (58 percent versus 24 percent)," says Paul Mueller, M.D., lead investigator, Mayo Clinic Department of General Internal Medicine. At Mayo Clinic the two-year survival rate for patients treated with LVAD is 74 percent. Therefore, the VAD is a long-term treatment for patients with severe heart failure.

Nevertheless, some patients treated with VADs experience complications (e.g., stroke) related to their treatment or their underlying disease and request withdrawal of VAD support.

Dr. Mueller and colleagues describe 14 patients who requested (or their surrogates requested) withdrawal of LVAD support and these requests were carried out by their physicians. Dr. Mueller and colleagues then describe the ethical and legal permissibility of carrying out such requests.

"If the patient (or their surrogate) concludes that VAD support is more burdensome than beneficial, they may request withdrawal of VAD support (that is, that the device be turned off)," says Dr. Mueller. "Assuming the patient (or surrogate) is informed regarding alternatives to and consequences of withdrawing VAD support, clinicians should carry out such requests or transfer the patient's care to another physician. The cause of death in these cases is the underlying heart disease, not assisted suicide or euthanasia. In our view, carrying out such requests is permissible in accordance with the principles that apply to withdrawing other life-sustaining treatments." Examples are hemodialysis, mechanical ventilation and artificial hydration and nutrition.


'/>"/>

Contact: Rebecca Finseth
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
Source:Eurekalert

Related medicine news :

1. Clinical trials can be improved by managing the learning curve
2. Mayo Clinic Center for Innovation to sponsor a collaborative symposium on innovations in health care experience and delivery
3. Sickle cell treatment developed at LA BioMed enters Phase 3 clinical trial
4. UC San Diego receives major clinical and translational science award
5. Hopkins faculty lead development of report to FDA on ethical, scientific issues related to post-market clinical trials
6. Mayo Clinic Proceedings: Sexual abuse survivors have increased of psychiatric disorders
7. Mayo Clinic study finds apathy and depression predict progression from mild cognitive impairment
8. Pediatric clinical studies appear prone to bias, Hopkins review shows
9. St. Elizabeth Dental Clinic Named one of the Best in the Nation
10. Electronic health records prime clinicians to provide progressive care to older adults
11. CELLING Treatment Centers New Clinic Revolutionizes Spinal Care with Adult Stem Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... (PRWEB) , ... April 26, 2017 , ... ... human performance, is proud to announce that it has received 510(k) clearance from ... the MyoCycle Home and the MyoCycle Pro. , Both devices are stationary cycling ...
(Date:4/25/2017)... (PRWEB) , ... April 25, ... ... based in Newport Beach, California, committed to raising awareness for Duchenne muscular ... results from its randomized CAP-1002 (cardiosphere-derived cells) Phase I/II HOPE clinical trial ...
(Date:4/25/2017)... BC (PRWEB) , ... April 25, 2017 , ... The ... from Richmond, BC, who live with dental fear and require sedation to receive dental ... at ease during various procedures, from hygienic cleanings to oral surgery, at their ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... unveiling cutting-edge birth defects research related to Zika virus during pregnancy, as well ... society for this important science. , The Teratology Society is ...
(Date:4/25/2017)... Clara, CA (PRWEB) , ... April 25, 2017 ... ... announces the addition of predictive analytics to its patient care management module. Using ... compliance even before a patient has been initiated on continuous positive airway pressure ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... VIEW, Calif. , April 19, 2017  IRIDEX ... it will release financial results for the first quarter ... 3, 2017.  The Company,s management team will host a ... 5:30 p.m. ET. Investors interested in listening ... (844) 707-0665 for domestic callers or (703) 326-3030 for ...
(Date:4/19/2017)... SAN DIEGO , April 19, 2017 /PRNewswire/ ... ("Sorrento"), an antibody-centric, clinical-stage biopharmaceutical company developing new ... today announced the closing of its previously announced ... common stock at a public offering price of ... commissions and estimated offering expenses payable by Sorrento.  ...
(Date:4/18/2017)... -- Cardinal Health (NYSE: CAH ) today is ... share (EPS) guidance and providing a preliminary view on ... this morning,s announcement of the planned acquisition of Medtronic,s ... Cardinal Health now believes that fiscal 2017 ... bottom of its previous guidance range of $5.35 to ...
Breaking Medicine Technology: